Vivo Bio Tech Limited , a prominent player in the biotech sector, has announced robust financial results for the first quarter ended June 30, 2025, demonstrating significant growth across key metrics.

Financial Highlights

• Total Income: Surged by 29.66% to Rs. 2,220.72 lakhs, compared to Rs. 1,712.71 lakhs in the same quarter last year.
• Profit Before Tax: Increased by 16.22% to Rs. 200.72 lakhs from Rs. 172.71 lakhs.
• Profit After Tax: Rose by 21.93% to Rs. 155.72 lakhs from Rs. 127.71 lakhs.
• Earnings Per Share: Improved to Rs. 1.05 from Rs. 0.92.

Operational Performance

The company's operational efficiency showed marked improvement:

Management Commentary

While specific management comments were not provided, the consistent growth across revenue and profit metrics indicates improved operational performance and potentially successful business strategies implemented by Vivo Bio Tech.

Market Disclosure

In compliance with regulatory requirements, Vivo Bio Tech Limited has published its un-audited financial results for the first quarter ended June 30, 2025, in both English and Telugu newspapers on August 14, 2025. This adherence to transparency norms underscores the company's commitment to keeping investors and stakeholders well-informed.

Outlook

The biotech sector continues to be a focus area for innovation and growth. Vivo Bio Tech's strong performance in Q1 FY2026 positions it well to capitalize on opportunities in this dynamic industry. Investors and analysts will likely keep a close watch on the company's future quarters to assess the sustainability of this growth trajectory.

As the biotech landscape evolves, Vivo Bio Tech's ability to maintain its growth momentum and operational efficiency will be crucial factors in determining its long-term success and market position.

Vivo Bio Tech Limited has successfully secured shareholder approval for increasing its authorized share capital and altering the Capital Clause of its Memorandum of Association. The resolution, passed through a postal ballot and e-voting process, marks a significant step for the company's potential future growth and capital structure modifications.

Voting Results

The shareholder voting, which concluded on August 2, saw overwhelming support for the proposed changes:

Out of the total 19,893,889 shares, 6,261,107 votes were cast, representing a 31.47% voter turnout. The Promoter and Promoter Group, holding 7,771,500 shares, showed strong support with 100% votes in favor and a 68.78% participation rate through e-voting.

Key Details

• Resolution Type: Ordinary Resolution
• Scrutinizer: Vinay Babu Gade (CS, Membership No. 20592)
• Record Date: June 27
• Total Shareholders on Record Date: 22,141

Implications

The approval to increase the authorized share capital could pave the way for Vivo Bio Tech to raise additional funds, potentially through the issuance of new shares. This move might be aimed at supporting the company's growth strategies, funding expansion plans, or strengthening its financial position.

Regulatory Compliance

In compliance with SEBI regulations, Vivo Bio Tech has disclosed the voting results and the Scrutinizer's Report to the BSE. The company has also made this information available on its official website ( www.vivobio.com ), ensuring transparency for all stakeholders.

The successful passage of this resolution demonstrates strong shareholder confidence in Vivo Bio Tech's strategic direction. As the company moves forward with its capital restructuring plans, investors and market watchers will likely keep a close eye on how this increased authorized share capital will be utilized to drive growth and create value.